First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Massachusetts General Hospital · Tennessee Oncology · +10 more institutions
Indexed incrossrefpubmed
Abstract
Background
-positive NSCLC is unclear.
Methods
-positive NSCLC who had received no previous systemic treatment for metastatic disease. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included independently assessed objective response and intracranial response. An interim analysis of efficacy was planned after approximately 133 of 177 (75%) expected events of disease progression or death had occurred.
Citation impact
1,053
total citations
- FWCI
- 72.51
- Percentile
- 100%
- References
- 29
Citations per year
Authors
14- ATAlice T. ShawCorresponding
Massachusetts General Hospital, Tennessee Oncology
- TMTodd M. Bauer
Sarah Cannon, Tennessee Oncology
- FDFilippo de Marinis
Tennessee Oncology, European Institute of Oncology
- EFEnriqueta Felip
Hebron University, Tennessee Oncology
- YGYasushi Goto
Tennessee Oncology, Tokyo National Hospital
Topics & keywords
Topics
Keywords
- Crizotinib
- Anaplastic lymphoma kinase
- ALK inhibitor
- Lung cancer
- Cancer research
- Medicine
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.